Strategia begins Phase I/IIa trial of anti-cancer agent to treat advanced hematologic malignancies
The anti-cancer agent is designed to treat relapsed or refractory acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The trial is being conducted
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.